Price inflation has led average European entry multiples to climb to 10.8x in the second quarter of 2017, up from 10.1x in Q1, according to the latest unquote" and Clearwater Multiples Heatmap Analysis.
New and historical backers invest in Belgium-based Imcyse, a developer of immunotherapies
Buyout of the baking product company is the GP's fifth UK deal since opening a Manchester office
Sale ends an eight-year holding period for the GP, which owned an 83.4% stake in the company
Fresh capital will be used to develop BioSerenity's products beyond their initial focus